SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCVS Group Regulatory News (CVSG)

Share Price Information for CVS Group (CVSG)

Share Price is delayed by 15 minutes
Get Live Data
1,215.00    -16.00 (-1.30%)
Bid:
1,215.00
Ask:
1,248.00
Spread: 33.00 (2.716%)
Market Cap: £847.40m
CVSG Live PriceLast checked at - London Stock Exchange

Intraday CVS Group Share Chart

Transaction in Own Shares

8 Dec 2025 07:00

RNS Number : 6187K
CVS Group plc
08 December 2025
 

08 December 2025

 

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

 

CVS announces that on 05 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

 

Date of purchase:

05/12/2025

Aggregate number of Ordinary Shares purchased:

12,974

Lowest price paid per share (GBp):

1,200.00

Highest price paid per share (GBp):

1,214.00

Volume weighted average price paid per share (GBp):

1,211.79

CVS intends to cancel all of the purchased Ordinary Shares.

 

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,961,055 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

 

The total number of voting rights in CVS is therefore 70,961,055 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

 

Since the commencement of the Share Buyback Programme, the Company has repurchased 779,728 Ordinary Shares in aggregate at a weighted average price of 1,215.61 pence per share.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

 

Individual transactions:

 

Number of

Ordinary Shares purchased

Transaction price (GBp share)

Time of

transaction (UK Time)

Transaction

reference number

Trading Venue

 

204

1202

05/12/2025 08:02:59

1345897338243595

XLON

82

1200

05/12/2025 08:08:15

1345897338244424

XLON

459

1212

05/12/2025 08:49:22

1345897338249263

XLON

120

1208

05/12/2025 08:55:35

1345897338249854

XLON

72

1210

05/12/2025 08:59:59

1345897338250281

XLON

444

1210

05/12/2025 08:59:59

1345897338250285

XLON

82

1210

05/12/2025 09:26:59

1345897338253361

XLON

252

1214

05/12/2025 10:03:32

1345897338256451

XLON

124

1212

05/12/2025 10:24:34

1345897338257876

XLON

262

1214

05/12/2025 11:37:41

1345897338263129

XLON

196

1214

05/12/2025 12:29:44

1345897338266064

XLON

111

1214

05/12/2025 12:29:44

1345897338266067

XLON

201

1212

05/12/2025 12:49:13

1345897338267042

XLON

201

1212

05/12/2025 12:49:13

1345897338267048

XLON

43

1212

05/12/2025 12:49:13

1345897338267049

XLON

201

1212

05/12/2025 12:49:13

1345897338267050

XLON

63

1212

05/12/2025 12:49:13

1345897338267051

XLON

201

1212

05/12/2025 13:06:51

1345897338268072

XLON

72

1214

05/12/2025 13:06:51

1345897338268069

XLON

1180

1212

05/12/2025 13:06:51

1345897338268076

XLON

201

1212

05/12/2025 13:06:51

1345897338268077

XLON

263

1212

05/12/2025 13:06:51

1345897338268078

XLON

15

1212

05/12/2025 13:06:51

1345897338268079

XLON

146

1212

05/12/2025 13:25:57

1345897338268965

XLON

186

1212

05/12/2025 13:25:57

1345897338268963

XLON

6315

1212

05/12/2025 13:25:57

1345897338268969

XLON

201

1212

05/12/2025 13:25:57

1345897338268976

XLON

62

1212

05/12/2025 13:25:57

1345897338268977

XLON

201

1212

05/12/2025 13:25:57

1345897338268978

XLON

122

1212

05/12/2025 13:25:57

1345897338268980

XLON

466

1212

05/12/2025 13:25:57

1345897338268981

XLON

72

1214

05/12/2025 13:56:32

1345897338271298

XLON

147

1212

05/12/2025 13:59:26

1345897338271706

XLON

7

1212

05/12/2025 14:25:29

1345897338273806

XLON

 

Contacts

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

 

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

 

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

 

Camarco (Financial PR) cvsg@camarco.co.uk

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

 

About CVS Group plc (www.cvsukltd.co.uk)

 

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

 

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

 

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSUPGPPPUPAPWM
Date   Source Headline
15th Jun 20267:00 amRNSTransaction in Own Shares
12th Jun 202611:08 amRNSHolding(s) in Company
12th Jun 202610:06 amRNSHolding(s) in Company
8th Jun 20262:43 pmRNSStandard form for notification of major holdings
8th Jun 20262:41 pmRNSUpdated: Transaction in Own Shares
8th Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20267:00 amRNSTotal Voting Rights
28th May 20267:00 amRNSPDMR Dealing
26th May 20267:02 amRNSChanges to NEDs' Responsibilities
26th May 20267:01 amRNSCommencement of Share Buyback Programme
26th May 20267:00 amRNSRefinancing, Launch of SBB and Acquisition
8th May 20263:55 pmRNSStandard form for notification of major holdings
30th Apr 20267:00 amRNSTotal Voting Rights
21st Apr 202612:46 pmRNSNon-Executive Director Appointment
20th Apr 20264:45 pmRNSStandard form for notification of major holdings
31st Mar 20267:00 amRNSTotal Voting Rights
30th Mar 20267:00 amRNSCEO retirement
25th Mar 20267:00 amRNSNon-Executive Director Changes
24th Mar 20267:13 amRNSResponse to CMA Summary Final Decision Report
27th Feb 20267:00 amRNSTotal Voting Rights
26th Feb 20267:00 amRNSInterim Results
30th Jan 20267:00 amRNSTotal Voting Rights
29th Jan 20262:02 pmRNSStandard form for notification of major holdings
29th Jan 20268:00 amRNSReadmission - CVS Group Plc
29th Jan 20267:00 amRNSAdmission to Trading on the Main Market of the LSE
28th Jan 20267:08 amRNSResponse to DEFRA consultation
27th Jan 20262:31 pmRNSStandard form for notification of major holdings
23rd Jan 202612:19 pmRNSPublication of Prospectus and Trading Update
23rd Jan 20267:00 amRNSProgramme completion and transaction in own shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20269:51 amRNSStandard form for notification of major holdings
19th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20264:24 pmRNSStandard form for notification of major holdings
14th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSBlock Listing Interim Review
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20264:31 pmRNSStandard form for notification of major holdings
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
6th Jan 20269:34 amRNSDirector/PDMR Shareholding
6th Jan 20267:00 amRNSTransaction in Own Shares
5th Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20267:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.